End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.7 CNY | +5.14% | +3.95% | -8.67% |
05-01 | NKFPharma Gets Nod to Register New Cancer Treatment | MT |
04-27 | Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.67% | 3.05B | D | ||
+27.07% | 681B | C+ | ||
+21.80% | 556B | B | ||
-5.18% | 361B | C+ | ||
+16.94% | 325B | B- | ||
+4.41% | 285B | C+ | ||
+14.00% | 235B | B+ | ||
+3.96% | 199B | B- | ||
-11.37% | 189B | A+ | ||
-3.65% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603707 Stock
- Ratings Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.